Press release
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
– Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi®
About this update from Incyte Corporation
[{"type":"text","content":"\n– Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y)\n\n\n– Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million]\n\n\n– Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y)\n\n\n– Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million]\n\n\n– Zynyz® (retifanlimab-dlwr) and Monjuvi® (tafasitamab-cxix) approved by the U.S. FDA for the first line treatment of adult patients with advanced squamous cell carcinoma of the anal canal (SCAC) and for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) in combination with rituximab and lenalidomide, respectively\n\n\n– Bill Meury appointed as President and Chief Executive Officer effective June 26, 2025, upon the retirement of Hervé Hoppenot\n\n\nConference Call and Webcast Scheduled Today at 8:00 a.m. ET\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio.\n\n\n\"As I begin my tenure as CEO, I look forward to leading Incyte through its next phase of growth and value creation for patients, partners and shareholders. Our second quarter results reflect strong growth for Jakafi® (ruxolitinib), Opzelura® (ruxolitinib) cream and Niktimvo™ (axatilimab), positioning us well to deliver on our 2025 objectives,\" said Bill Meury, Chief Executive Officer, Incyte. \"During the quarter, we achieved two regulatory milestones with the approvals of Zynyz® (retifanlimab-dlwr) for squamous cell anal carcinoma and Monjuvi® (tafasitamab-cxix) for follicular lymphoma, further expanding our ability to address patients' needs. Continued progress and diversification of our portfolio, including advancements with povorcitinib and mutCALR, are strengthening the foundation for sustainable, long-term growth.”\n\n\nKey Commercial Highlights\n\n\nJakafi:\n\n\nNet product revenues for the second quarter 2025 ...